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Progestins, high-dose oestrogens, selective oestrogen receptor
modulators (SERMs), aromatase inhibitors (AIs), and, most
recently, the new type of oestrogen receptor (ER) antagonist
fulvestrant (‘Faslodex’) have all been used for the treatment of
hormone-sensitive advanced breast cancer in postmenopausal
women. Tamoxifen was the ‘gold standard’ hormonal therapy for
both pre- and postmenopausal women for many years. Recently,
the third-generation nonsteroidal AIs anastrozole and letrozole
and the steroidal AI exemestane have been shown to be more
effective than tamoxifen as first-line treatment in postmenopausal
women with hormone-sensitive advanced disease, leading to
approval in this treatment setting. Different types of endocrine
treatments are associated with different side effects, which may
include nausea, vaginal bleeding and weight gain. SERMs such as
tamoxifen have oestrogen agonist effects in a number of tissues
including breast and uterus, which can cause ‘tumour flare’ and
may increase the risk of endometrial cancer. Effects on lipid profile
may increase the risk of thromboembolic events.
Most patients will eventually become resistant to endocrine
agents. In an attempt to extend the time window in which well-
tolerated treatments may be used, it is common clinical practice to
use two or more different endocrine therapies in sequence. For this
to be successful, it is necessary to use endocrine agents with
different mechanisms of action that do not possess crossresistance
with any hormonal therapies previously used. New endocrine
therapies with novel mechanisms of action provide opportunities
not only for optimising the efficacy of breast cancer treatment, but
may also allow a longer time in which endocrine therapies can be
used before reliance upon cytotoxic chemotherapy is necessary.
Fulvestrant is a new type of endocrine agent for the treatment of
hormone-sensitive advanced breast cancer in postmenopausal
women who have progressed on prior endocrine therapy. Unlike
tamoxifen, fulvestrant has no oestrogen agonist activity. This
supplement contains four papers that together provide a
comprehensive review of fulvestrant. The first of these, by C Kent
Osborne, Robert Nicholson and Alan Wakeling, provides an
overview of the current understanding of ER signalling and its
effect on breast cancer development. It details how fulvestrant acts
to produce downregulation of cellular levels of the ER. Following
this, John Robertson and Mike Harrison review the pharmacoki-
netics and metabolism of fulvestrant. In the third paper, John
Robertson and Ignace Vergote report on the clinical data for
fulvestrant, from the early efficacy and tolerability studies through
to the three randomised phase III trials for fulvestrant that have
been conducted in postmenopausal women with hormone-
sensitive advanced breast cancer; two of these compared
fulvestrant with anastrozole in patients who had progressed on
prior endocrine therapy, and the third compared fulvestrant with
tamoxifen as first-line endocrine treatment. Finally, Stephen
Johnston reviews the evidence suggesting the versatility of
fulvestrant in the sequencing of hormonal therapy, and considers
the options for optimising the endocrine sequence cascade.
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